AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Three ...

The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

Discover the latest insights and trends in personal finance with this comprehensive article written by a financial expert.

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...